Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer –– Comprehensive ...

In a recent study published in Nature Communications, researchers described an approach to edit the recombination-activating gene 2 (RAG2) locus for therapeutic applications. Study: CRISPR-Cas9 ...

James Dentzer, President and CEO, emphasized continued progress in the TakeAim Lymphoma study evaluating emavusertib in combination with ibrutinib in primary CNS lymphoma (PCNSL), stating the company ...

Three different HIV antibodies each independently protected monkeys from acquiring simian-HIV (SHIV) in a placebo-controlled proof-of-concept study intended to inform development of a preventive HIV ...

Patients with pulmonary sarcoidosis showed significantly higher uptake of the VAP-1–targeted PET tracer in the lungs and ...

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, ...

Biohaven’s phase 2 proof-of-concept study with BHV-7000 in major depressive disorder fails to meet its primary endpoint: New Haven, Connecticut Monday, December 29, 2025, 13:00 ...

The proof-of-concept open-label study evaluated the safety and tolerability, function of regulatory T cells (Tregs), biomarkers, and preliminary efficacy (as measured by the ALSFRS-R scale) of COYA ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Xeno Biosciences Inc., a clinical stage drug discovery and development company advancing therapeutics for the treatment of obesity and metabolic diseases, announced ...

Oncolytics Biotech (ONCY) is a good speculative biotech play to look into. The reason why I state that is because it has been able to establish proof of concept in two large markets. These two markets ...

Researchers say they have successfully used a cell's natural process for making proteins to 'slide' genetic instructions into a cell and produce critical proteins missing from those cells. Johns ...